Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL

被引：0
|
作者：
Christian Rübe
T. Phu Nguyen
Maritta Klöss
Markus Loeffler
Lorenz Trümper
Michael Pfreundschuh
机构：
[1] Departments for Radiotherapy,
[2] Saarland University,undefined
[3] Germany,undefined
[4] e-mail: ruebe@med-rz.uni-saarland.de,undefined
[5] Tel.: +49 6841 164606,undefined
[6] Fax: +49 6841 164699,undefined
[7] Internal Med. I,undefined
[8] Saarland University,undefined
[9] Germany,undefined
[10] Dept. Med. Inf.,undefined
[11] Statistics and Epidemiology,undefined
[12] University of Leipzig,undefined
[13] Germany,undefined
来源：
Annals of Hematology | 2001年 / 80卷 / Suppl 3期
关键词：
Keywords Aggressive NHL, bulky disease, radiotherapy;
D O I：
10.1007/PL00022798
中图分类号：
学科分类号：
摘要：
The impact of radiotherapy in aggressive NHL is not well defined. In the NHL B-94 trial of the DSHNHL, an irradiation of bulky disease areas was done after completing 6 cycles of CHOP/CHOEP chemotherapy. In the entire patient group, including those patients with extranodal disease and those who did not receive the complete chemotherapy, bulky disease was a significant independent prognostic factor concerning recurence-free survival (66.1% (no bulk) vs. 53.5% (bulk), p=0.0001). Out of 366 patients with nodal disease only and 6 cycles of chemotherapy according to the protocol, 84 of 91 patients with bulky disease were irradiated with 36 Gy. In this group of patients the prognostic impact of bulky disease could not be shown any longer (recurrence-free survival 77.3% (no bulk) vs. 74.1% (bulk). Localized radiotherapy of bulky disease areas may therefore have contributed to an improvement in outcome in this high-risk group.
引用
收藏
页码：B84 / B85
相关论文
共 29 条
  • [1] Consolidation radiotherapy to bulky disease in aggressive NHL.: First results of the NHL B-94 trial of the DSHNHL
    Rübe, C
    Nguyen, TP
    Klöss, M
    Loeffler, M
    Trümper, L
    Pfreundschuh, M
    ANNALS OF HEMATOLOGY, 2001, 80 : B84 - B85
  • [2] Rituximab:: First report of a phase II (PII) trial in NHL patients (pts) with bulky disease.
    Davis, TA
    White, CA
    Grillo-López, AJ
    Velásquez, WS
    Link, B
    Maloney, DG
    Dillman, RO
    Williams, ME
    Mohrbacher, A
    Weaver, R
    Dowden, S
    Levy, R
    BLOOD, 1998, 92 (10) : 414A - 414A
  • [3] Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
    Jaeger, Ulrich
    Trneny, Marek
    Melzer, Helen
    Praxmarer, Michael
    Nawarawong, Weerasak
    Ben Yehuda, Dina
    Goldstein, David
    Mihaljevic, Bilijana
    Ilhan, Osman
    Ballova, Veronika
    Hedenus, Michael
    Hsiao, Liang-Tsai
    Au, Wing-Yan
    Burgstaller, Sonja
    Weidinger, Gerhard
    Keil, Felix
    Dittrich, Christian
    Skrabs, Cathrin
    Klingler, Anton
    Chott, Andreas
    Fridrik, Michael A.
    Greil, Richard
    HAEMATOLOGICA, 2015, 100 (07) : 955 - 963
  • [4] Idarubicin 15 mg is dose-equivalent to doxorubicin 50 mg in the treatment of aggressive NHL but more toxic:: Results of the NHL-CIVEP phase I/II dose finding trial of the German High Grade NHL Study Group (DSHNHL).
    Trümper, L
    Klöss, M
    Schmits, R
    Kaiser, U
    Engert, A
    Franke, A
    Kroschinsky, F
    Koch, P
    Loeffler, M
    Pfreundschuh, M
    BLOOD, 2000, 96 (11) : 250B - 250B
  • [5] Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
    Pfreundschuh, M
    Trümper, L
    Kloess, M
    Schmits, R
    Feller, AC
    Rübe, C
    Rudolph, C
    Reiser, M
    Hossfeld, DK
    Eimermacher, H
    Hasenclever, D
    Schmitz, N
    Loeffler, M
    BLOOD, 2004, 104 (03) : 634 - 641
  • [6] Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial"
    Vassilakopoulos, Theodoros P.
    Apostolidis, John
    Angelopoulou, Maria K.
    HAEMATOLOGICA, 2015, 100 (11) : E480 - E481
  • [7] 2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL):: Results of the completed NHL-B-2 trial of the DSHNHL.
    Pfreundschuh, M
    Truemper, L
    Kloess, M
    Schmits, R
    Schmitz, N
    Glass, B
    Engert, A
    Rudolph, C
    Mezger, D
    Hossfeld, D
    Loeffler, M
    BLOOD, 2002, 100 (11) : 774A - 774A
  • [8] Rituximab (Mabthera) improves the treatment results of DHAP-VIMDHAP and ASCT in Relapsed/Progressive aggressive CD20+ NHL.: A prospective randomized HOVON trial.
    Vellenga, Edo
    Notenboom, Annelise
    van 't Veer, Mars
    Zijlstra, Josee
    Fibbe, Willem E.
    van Oers, Rien
    van Imhoff, Gustaaf W.
    Lugtenburg, Elly
    Huijgens, P. C.
    BLOOD, 2006, 108 (11) : 102A - 102A
  • [9] Early response to a short course of induction chemotherapy overcomes the prognostic role of IPI in patients with aggressive NHL. Preliminary results of the GISL LA05 trial.
    Di Renzo, Nicola
    Luminari, Stefano
    Montanini, Antonella
    Petrini, Mario
    Brugiatelli, Maura
    Gobbi, Paolo G.
    Stelitano, Caterina
    Angrilli, Francesco
    Musso, Maurizio
    Baldini, Luca
    Mazza, Patrizio
    Pennese, Elsa
    Federico, Massimo
    BLOOD, 2006, 108 (11) : 689A - 689A
  • [10] Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:: results of the NHL-B1 trial of the DSHNHL
    Pfreundschuh, M
    Trümper, L
    Kloess, M
    Schmits, R
    Feller, AC
    Rudolph, C
    Reiser, M
    Hossfeld, DK
    Metzner, B
    Hasenclever, D
    Schmitz, N
    Glass, B
    Rübe, C
    Loeffler, M
    BLOOD, 2004, 104 (03) : 626 - 633
123